<DOC>
	<DOCNO>NCT01050283</DOCNO>
	<brief_summary>This study determine whether [ 18F ] -fluorodeoxyglucose-positron emission tomography ( FDG-PET ) use screen activity novel pancreatic cancer treatment .</brief_summary>
	<brief_title>A Study Evaluate 18F-FDG PET ( Fluorodeoxyglucose-positron ) Patients With Pancreatic Cancer ( MK-0000-144 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>Patient diagnosis Stage IV pancreatic adenocarcinoma distant metastases Patient schedule receive standard chemotherapy contain gemcitabine Patient receive prior systemic therapy advance pancreatic adenocarcinoma Patient must available periodic blood sampling , studyrelated assessment , management treat institution Patient open abdominal surgery within 6 week screen visit Patient radiotherapy thorax , abdomen , pelvis within 6 month screen visit Patient active infection , inflammation , unresolved bowel obstruction Patient poorly control diabetes</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Advanced pancreatic adenocarcinoma</keyword>
</DOC>